Cardioselective β-Blockers in Patients with Reactive Airway Disease

  1. Shelley R. Salpeter, MD;
  2. Thomas M. Ormiston, MD; and
  3. Edwin E. Salpeter, PhD
  1. From Stanford University School of Medicine, Palo Alto, California; Santa Clara Valley Medical Center, San Jose, California; and Cornell University, Ithaca, New York.
    1. Figure 1. Diamonds represent the extent of the confidence intervals. For group 1, test for heterogeneity, > 0.2; test for overall effect, < 0.001. For group 2, test for heterogeneity, = 0.05; test for overall effect, = 0.15. For both groups, test for heterogeneity, = 0.09; test for overall effect, < 0.001.
      View larger version:
        Figure 1. Diamonds represent the extent of the confidence intervals. For group 1, test for heterogeneity, > 0.2; test for overall effect, < 0.001. For group 2, test for heterogeneity, = 0.05; test for overall effect, = 0.15. For both groups, test for heterogeneity, = 0.09; test for overall effect, < 0.001. Effects of treatment on FEV1 for single-dose studies.PPPPPP
      • Figure 2. Diamonds represent the extent of the confidence intervals. For group 1, test for heterogeneity, < 0.001; test for overall effect, < 0.001. For group 2, test for heterogeneity, > 0.2; test for overall effect, = 0.2. For both groups, test for heterogeneity, < 0.001; test for overall effect, < 0.001.
        View larger version:
          Figure 2. Diamonds represent the extent of the confidence intervals. For group 1, test for heterogeneity, < 0.001; test for overall effect, < 0.001. For group 2, test for heterogeneity, > 0.2; test for overall effect, = 0.2. For both groups, test for heterogeneity, < 0.001; test for overall effect, < 0.001. Effects of treatment after use of β2-agonists on FEV1 for single-dose studies.PPPPPP
        • Figure 3. Diamonds represent the extent of the confidence intervals. For group 1, test for heterogeneity, > 0.2; test for overall effect, 0.17. For group 2, test for overall effect, > 0.2. For both groups, test for heterogeneity, = 0.18; test for overall effect, > 0.2.
          View larger version:
            Figure 3. Diamonds represent the extent of the confidence intervals. For group 1, test for heterogeneity, > 0.2; test for overall effect, 0.17. For group 2, test for overall effect, > 0.2. For both groups, test for heterogeneity, = 0.18; test for overall effect, > 0.2. Effects of treatment on FEV1 for continued treatment studies.PP =PPP
          • Figure 4. Diamonds represent the extent of the confidence intervals. For group 1, test for heterogeneity, = 0.013; test for overall effect, 0.003. For group 2, test for overall effect, 0.2. For both groups, test for heterogeneity, < 0.01; test for overall effect, 0.01.
            View larger version:
              Figure 4. Diamonds represent the extent of the confidence intervals. For group 1, test for heterogeneity, = 0.013; test for overall effect, 0.003. For group 2, test for overall effect, 0.2. For both groups, test for heterogeneity, < 0.01; test for overall effect, 0.01. Effects of treatment after use of β2-agonists on FEV1 for continued treatment studies.PP =P >PP =
            • Appendix Figure.
              View larger version:
                Appendix Figure. Results of search for and selection of trials.

              Summary for Patients

              • Summaries for Patients:Are Beta-1–Blockers Safe for Patients with Lung Disease? Ann Intern Med November 5, 2002 137:I-31
              « Previous | Next Article »Table of Contents

              This Article

              1. Ann Intern Med November 5, 2002 vol. 137 no. 9 715-725
              1. AbstractFREE
              2. » Figures
              3. Full Text
              4. Full Text (PDF)
                1. Summary for Patients

              Rapid Responses

              1. Submit a response
              2. No responses published

              Current Issue

              1. November 17, 2009, 151 (10)
              1. Alert me to current issues